Aclarion, Inc. filings document the company’s healthcare technology business, public-company governance, security structure and material corporate events. Proxy materials cover annual-meeting matters such as director elections, auditor ratification and amendments to the 2022 Equity Incentive Plan.
Form 8-K disclosures record board-authorized capital actions, stockholder rights agreement matters, registered direct offerings, common stock and pre-funded warrant terms, and modifications affecting security holders. The filing record also includes capital-structure, material-agreement, clinical or regulatory disclosure categories, and emerging growth company reporting status.
Aclarion, Inc. reported a larger net loss for the quarter ended March 31, 2026, while significantly strengthening its cash position through new equity financing. Revenue rose modestly to $21,140 from $18,991, driven mainly by more Nociscan reports sold in the U.K.
Operating expenses nearly doubled to $2.99 million, reflecting higher sales and marketing spending around the CLARITY Trial, greater research and development, and increased general and administrative costs such as investor relations and Delaware franchise taxes. Net loss widened to $2.85 million from $2.04 million, or $(1.34) per share.
Cash, cash equivalents and restricted cash increased to $19.03 million, supported by a January 2026 registered direct offering of common stock and pre-funded warrants that generated roughly $10.4 million in gross proceeds. The company expects its current cash to fund operations into the second half of 2027. Subsequent to quarter-end, the board approved a $2.5 million share repurchase program and adopted a stockholder rights agreement intended to discourage hostile accumulations of its stock.
Aclarion, Inc. director Scott Breidbart made an open-market purchase of Common Stock. On May 12, 2026, he bought 5,664 shares at a price of $3.18 per share in a public market transaction. Following this trade, his directly held position stands at 5,664 shares.
Aclarion, Inc. director Neal David K completed an open-market purchase of 2,500 shares of Aclarion common stock on May 11, 2026. The shares were bought at an average price of $3.10 per share. Following this transaction, he directly holds 2,502 common shares of Aclarion.
Aclarion, Inc. director and CEO Brent Ness reported an open-market purchase of company stock. He bought 6,289 shares of Common Stock on the public market at a price of $3.18 per share. After this transaction, he directly owns 6,300 shares of Aclarion Common Stock.
Aclarion, Inc. director William Wesemann bought shares of the company in the open market. On 5/6/2026, he completed an open-market purchase of 1,562 shares of Aclarion common stock at a price of $3.30 per share. After this transaction, his direct holdings total 1,563 common shares.
Aclarion, Inc. is asking stockholders to vote at its 2026 annual meeting on June 4, 2026 in Broomfield, Colorado. Stockholders will elect seven directors, ratify Haynie & Company as independent auditor for the year ending December 31, 2026, and consider a major change to the company’s equity plan.
The board proposes amending the 2022 Equity Incentive Plan to increase the share reserve from 42,974 to 500,000 shares and to raise the per-participant annual limit on equity awards from 52 to 250,000 shares for employees, consultants, and non-employee directors. Aclarion reports 2,462,250 common shares outstanding as of April 10, 2026, the record date for voting. The company remains an emerging growth company and highlights its governance structure, independent board committees, and policies on insider trading, clawbacks, and director nominations. The board recommends voting FOR all three proposals.
Aclarion, Inc. has authorized a stock repurchase program of up to $2.5 million of its outstanding common shares. The company expects to carry out repurchases over the next 12 months, using methods such as open market purchases, block trades, privately negotiated deals, and 10b5-1 plans.
Aclarion plans to fund the program with existing cash and cash equivalents. As of March 31, 2026, it held approximately $19.0 million in cash and cash equivalents, which management believes is sufficient to support operations through key milestones, including the initial milestone of the CLARITY randomized trial.
Management describes the buyback as part of disciplined capital allocation and states they believe the current share price does not fully reflect the company’s Nociscan platform and long-term growth opportunity. The program is flexible and may be suspended, modified, or discontinued at any time.
Aclarion, Inc. is soliciting proxies for its 2026 Annual Meeting to be held June 4, 2026. Shareholders of record as of April 10, 2026 may vote on: (1) election of seven directors, (2) ratification of Haynie & Company as auditor, and (3) an amendment to the 2022 Equity Incentive Plan to increase the share reserve to 500,000 and raise per-participant annual limits.
The board recommends a vote FOR all proposals. Proxy materials and the 2025 Annual Report are available at the link provided in the notice. Attendance is in person only at the company’s Broomfield, Colorado offices.
SEG Opportunity Fund, LLC reports beneficial ownership of 244,043 shares of Aclarion, Inc. common stock, equal to 9.98% of the class. The filing states this position is based on 2,444,871 shares outstanding as of March 25, 2026. The statement lists shared voting and dispositive power over the 244,043 shares and is signed by Joseph Reda as Manager.
Aclarion, Inc. adopted a limited-duration stockholder rights plan that issues one right for each share of common stock and each Rights-Eligible Warrant outstanding as of March 30, 2026. Each right lets holders buy one one-thousandth of a share of Series D Junior Participating Preferred Stock at $14.00, subject to adjustment.
The plan is triggered if a person or group acquires 10% or more of common stock without board approval, with existing holders at or above that level grandfathered so long as they do not increase ownership. If triggered, other holders can buy securities at a 2x value multiple, diluting the acquirer.
The plan expires on March 18, 2027 unless earlier redeemed for $0.001 per right, exchanged into common or preferred shares, or terminated in connection with a board-approved merger. Aclarion also designated 10,000 shares of Series D Junior Participating Preferred Stock to support the plan.